SCHEMBL2902390

SCHEMBL2902390

O=C(O)c1cccc(NC(c2cccnc2)c2ccc(OC(F)F)c(OC3CCC3)n2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 7/20 0.49
PDE4B Q07343 5/20 0.49
PDE4C Q08493 5/20 0.49
PDE4D Q08499 5/20 0.49
ADRB3 P13945 3/20 0.36
ADRB1 P08588 2/20 0.36
SYK P43405 1/20 0.36
RCE1 Q9Y256 2/20 0.35
ABL1 P00519 1/20 0.35
BCR P11274 1/20 0.35
PRKCA P17252 1/20 0.35
MKNK1 Q9BUB5 1/20 0.35
MKNK2 Q9HBH9 1/20 0.35
MAPT P10636 2/20 0.35
LMNA P02545 1/20 0.35
POLB P06746 1/20 0.35
KMT2A Q03164 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
EPHX2 P34913 1/20 0.35
NPC1 O15118 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2907952 0.90 PDE4A (0.42) PDE4APDE4BPDE4CPDE4DADRB3
SCHEMBL2910712 0.90 PDE4A (0.40) PDE4APDE4BPDE4CPDE4DADRB3
SCHEMBL2905266 0.89 PDE4A (0.44) PDE4APDE4BPDE4CPDE4DADRB3
SCHEMBL2905902 0.87 SYK (0.39) PDE4APDE4BPDE4CPDE4DSYK
SCHEMBL2910233 0.87 PDE4D (0.51) PDE4APDE4BPDE4CPDE4DSYK
SCHEMBL2908789 0.86 ALDH1A1 (0.40) PDE4APDE4BPDE4CPDE4DSYK
SCHEMBL2902486 0.81 PDE4D (0.38) PDE4APDE4BPDE4CPDE4D
SCHEMBL2907262 0.81 PDE4D (0.38) PDE4APDE4BPDE4CPDE4D
SCHEMBL2910343 0.79 LMNA (0.41) SYKRCE1ABL1BCRPRKCA
SCHEMBL2903328 0.77 CSF1R (0.42) RCE1ABL1BCRPRKCALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1692109-B1 PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED DIARYLAMINE ANALOGS MEMORY PHARM CORP (US) 2010-08-18 EP claimed
US-20050222207-A1 Phosphodiesterase 4 inhibitors, including N-substituted diarylamine analogs MEMORY PHARMACEUTICAL CORPORATION 2005-10-06 US claimed
EP-1692109-B1 PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED DIARYLAMINE ANALOGS MEMORY PHARM CORP (US) 2010-08-18 EP disclosed
EP-1692109-A2 PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED DIARYLAMINE ANALOGS Memory Pharmaceuticals Corporation (US) 2006-08-23 EP disclosed
US-20050222207-A1 Phosphodiesterase 4 inhibitors, including N-substituted diarylamine analogs MEMORY PHARMACEUTICAL CORPORATION 2005-10-06 US disclosed
WO-2005061458-A2 PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED DIARYLAMINE ANALOGS MEMORY PHARMACEUTICALS CORPORATION (US) 2005-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050222207-A1 Phosphodiesterase 4 inhibitors, including N-substituted diarylamine analogs PDE4A, PDE4B, PDE3B PDE4A 1/4885PDE4B 2/4885PDE4C 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.